{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:58:04Z","timestamp":1791557884376,"version":"4.3.4"},"reference-count":0,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,1]]},"abstract":"<jats:p>During the last fifteen years, semicarbazones have been extensively investigated for their anticonvulsant properties. 4-(4-Flurophenoxy) benzaldehyde semicarbazone (C0102862, V102862) was discovered as a lead molecule and is being developed as a potent antiepileptic drug, with maximal electroshock (MES) <jats:italic>ED<\/jats:italic>50 of <jats:italic>i.p. <\/jats:italic>12.9 mg kg-1. In MES (oral screen), this compound has a protective index (<jats:italic>PI <\/jats:italic>= <jats:italic>TD<\/jats:italic>50\/<jats:italic>ED<\/jats:italic>50 &gt; 315) higher than carbamazepine (<jats:italic>PI <\/jats:italic>101), phenytoin (<jats:italic>PI <\/jats:italic>&gt; 21.6) and valproate (<jats:italic>PI<\/jats:italic> 2.17). The compound is a potent sodium channel blocker. Other semicarbazones have demonstrated activity in various chemoshock screens, like subcutaneous pentylenetetrazole, subcutaneous strychnine, subcutaneous picrotoxin and subcutaneous bicculine. Semicarbazones are also GABA-transaminase inhibitors. Extensive structure- -activity relationship has demonstrated that F, Cl, Br and NO2 substituents in the arylhydrophobic pocket and a hydrogen bonding domain (HBD) are generally found in active anticonvulsant agents.<\/jats:p>","DOI":"10.2478\/v10007-012-0030-1","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T14:32:37Z","timestamp":1358519557000},"page":"263-286","source":"Crossref","is-referenced-by-count":24,"title":["Semicarbazone \u2013 a versatile therapeutic pharmacophore for fragment based anticonvulsant drug design"],"prefix":"10.2478","volume":"62","author":[{"given":"Surendra","family":"Nath Pandeya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","container-title":["Acta Pharmaceutica"],"original-title":[],"link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/acph\/62\/3\/article-p263.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/view\/j\/acph.2012.62.issue-3\/v10007-012-0030-1\/v10007-012-0030-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T18:29:12Z","timestamp":1590863352000},"score":1,"resource":{"primary":{"URL":"https:\/\/content.sciendo.com\/doi\/10.2478\/v10007-012-0030-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":0,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.2478\/v10007-012-0030-1","relation":{},"ISSN":["1846-9558","1330-0075"],"issn-type":[{"value":"1846-9558","type":"electronic"},{"value":"1330-0075","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,1]]}}}